{"prompt": "['Trelagliptin-4002', 'Page 29 of 66', 'Version 1.0', 'November 2, 2016', \"study subject's health, or when the study subject is unwilling to continue study participation\", 'because of the adverse event.', '2. Major protocol deviation', 'When it is discovered after randomization that a study subject does not meet the eligibility', 'criteria or is not adhering to the protocol, and continued participation in the study would impose', \"an unacceptable risk to the study subject's health.\", '3. Lost to follow-up', 'When the study subject failed to make visits and could not be contacted despite the attempts to', 'contact the study subject.', '4. Voluntary termination', 'When the study subject wishes to withdraw from the study. The reason for discontinuation shall', 'be obtained to the extent possible.', '5.', 'Study termination', 'When the sponsor or a committee such as the Ethical Review Board or regulatory authority has', 'decided to terminate the study. Refer to Section 6.3.1 for details.', '6. Pregnancy', 'When a female study subject was found to be pregnant.', 'Note: The study subject must discontinue the study immediately after she was found to be', 'pregnant. Refer to Section 9.1.13 for the procedures.', '7. Lack of efficacy', 'When efficacy of the study drug is not evident and continuation of the study may pose an', 'unacceptable risk to the study subjects in the opinion of the principal investigator or', 'investigator.', '8. Others', 'When the principal investigator or investigator determined to terminate the study for other', 'reasons.', 'The specific reasons should be recorded on the CRF.', '7.6', 'Procedures for discontinuation of individual study subjects', \"The principal investigator or investigator shall terminate a study subject's study participation when\", 'the study subject meets the criteria described in Section 7.5. Individual study subjects may', 'discontinue their study participation without giving a reason at any time during the study. Should a', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 30 of 66', 'Version 1.0', 'November 2, 2016', \"study subject's participation be discontinued, the primary reason for termination shall be recorded on\", 'the CRF by the principal investigator or investigator. In addition, efforts shall be made to perform all', 'tests/observations/evaluations scheduled at the time of discontinuation.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 31 0f 66', 'Version 1.0', 'November 2, 2016', '8.0', 'STUDY TREATMENT', 'This section indicates the treatment regimen of this clinical research. See the latest package insert for', 'details and handling of each drug.', '8.1', 'Study drug and Comparative drug', '8.1.1', 'Study drug', 'Generic name: Trelagliptin Succinate', 'Chemical name: 2-(|6-[(3R)-3-Aminopiperidin-1-yl]-3-methyl-2, 4-dioxo-3, 4- dihydropyrimidin', '-', '1(2H)-yl} methyl)-4-fluorobenzonitrile monosuccinate', '<Dose and administration method>', 'Trelagliptin: Trelagliptin 100 mg is orally administered once weekly. Trelagliptin 50 mg is oraly', 'administered once weekly in patients with moderate renal impairment.', '8.1.2 Comparative drug', 'Daily DPP-4 inhibitor: Inhibitors shown in Table 8.a are orally administered at the dosage and', 'administration instructed in the package inserts of each drug.', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}